Miguel Sieler

Miguel Sieler Truffle Capital

Miguel is the Managing Director of Neovacs since October 2013 (Neovacs is a biotechnology company in Truffle’s portfolio, focused on the development of therapeutic vaccines for the treatment of autoimmune and inflammatory diseases and cancer.

He has over 30 years’ experience within the chemical and pharmaceutical industry. Miguel held several senior posts from 1975 to 2008 at the Bayer group in Korea, Germany, Belgium, Brazil and France. He was the CEO of Bayer Pharma France from 1995 to 1998, and Chairman of the Bayer Group in France from 1998 to 2008. Bayer is a renowned company within the medical sector.

He is Member of the Board of Directors of Nexity S.A.

Law graduate from the University of Tubingen (Germany) and graduate of the Institut d’Etudes Politiques in Paris.